Riskpilot← Back to searchSign inGet full accessSIMULPHARMA ApS
APSActiveCVR 32832075Marievej 24, 1. thWholesale of other machinery and equipment · NACE 4664Est. 20101 employees
Revenue 2024
DKK 159K
+38% vs 2023
EBITDA margin
25.9%
+172% vs 2023
Equity ratio
83.5%
Financial strength
Net profit 2024
DKK 41K
+172% vs 2023
| Revenue | DKK 159K | +38% |
| EBITDA | DKK 41K | +172% |
| Net profit | DKK 41K | +172% |
| Total assets | DKK 76K | +240% |
| Equity | DKK 64K | +184% |
| Employees | 1 | — |
Legal name
SIMULPHARMA ApS
CVR number
32832075
Legal form
Anpartsselskab
NACE code
4664 · Wholesale of other machinery and equipment
Founded
23. marts 2010
Share capital
DKK 80.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er at sælge maskiner til og servicere phzrmeceutiske virksomheder over hele Europa.
Address
Marievej 24, 1. th
Phone
+4551828267
Email
gulli@simulpharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 639 | 526 | 774 | 885 | 1.077 | 988 | 958 | 905 | 719 | 636 | 484 | 115 | 159 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 19 | 1 | 43 | 18 | 131 | 6 | 39 | -15 | 43 | -84 | -58 | -57 | 41 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 19 | 1 | 43 | 18 | 131 | 6 | 39 | -15 | 43 | -84 | -58 | -57 | 41 |
| Net financials | -2 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | -0 | -1 | -0 | 0 | 0 |
| Profit before tax | 18 | 2 | 43 | 4 | 131 | 6 | 39 | -15 | 43 | -85 | -58 | -57 | 41 |
| Tax | -0 | -0 | -0 | -0 | 24 | 1 | 9 | -2 | 6 | -2 | -0 | -0 | -0 |
| Net profit | 18 | 2 | 0 | 4 | 107 | 5 | 30 | -13 | 36 | -83 | -58 | -57 | 41 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 49 | 50 | 93 | 104 | 266 | 194 | 230 | 211 | 245 | 138 | 90 | 22 | 76 |
| Equity | 49 | 50 | 51 | 55 | 163 | 167 | 198 | 185 | 221 | 138 | 80 | 22 | 64 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 0 | 42 | 49 | 103 | 27 | 32 | 26 | 24 | 0 | 11 | 0 | 13 |
| Total debt | 0 | 0 | 42 | 49 | 103 | 27 | 32 | 26 | 24 | 0 | 11 | 0 | 13 |
EBITDA margin
25.9%
This company
15.8%
Market median
+64% vs market
20122024
Equity ratio
83.5%
This company
38.2%
Market median
+119% vs market
20122024
Return on equity
64.8%
This company
18.4%
Market median
+252% vs market
20122024
Net profit margin
26.0%
This company
8.1%
Market median
+221% vs market
20122024
Asset turnover
2.08×
This company
1.12×
Market median
+86% vs market
20122024
Debt / equity
0.20×
This company
0.62×
Market median
+68% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
No data on file.
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of SIMULPHARMA ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|